Andrew Gengos Acquires 5,000 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Stock

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) CFO Andrew Gengos purchased 5,000 shares of the firm’s stock in a transaction on Monday, June 16th. The stock was bought at an average price of $3.95 per share, with a total value of $19,750.00. Following the completion of the purchase, the chief financial officer now owns 15,000 shares of the company’s stock, valued at approximately $59,250. This represents a 50.00% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Andrew Gengos also recently made the following trade(s):

• On Friday, June 13th, Andrew Gengos purchased 10,000 shares of Terns Pharmaceuticals stock. The stock was bought at an average price of $3.73 per share, with a total value of $37,300.00.

Terns Pharmaceuticals Trading Up 2.6%

Shares of NASDAQ TERN opened at $4.00 on Thursday. Terns Pharmaceuticals, Inc. has a 12 month low of $1.87 and a 12 month high of $11.40. The stock has a 50 day moving average of $3.12 and a 200-day moving average of $3.99. The company has a market capitalization of $349.36 million, a P/E ratio of -3.67 and a beta of -0.18.

Terns Pharmaceuticals (NASDAQ:TERN) last issued its earnings results on Thursday, May 8th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.03. Analysts predict that Terns Pharmaceuticals, Inc. will post -1.19 EPS for the current fiscal year.

Analysts Set New Price Targets

TERN has been the subject of a number of analyst reports. BMO Capital Markets decreased their price target on Terns Pharmaceuticals from $26.00 to $15.00 and set an “outperform” rating for the company in a research note on Tuesday, May 13th. William Blair restated a “market perform” rating on shares of Terns Pharmaceuticals in a research note on Friday, March 21st. Finally, JMP Securities restated a “market outperform” rating and issued a $20.00 price target on shares of Terns Pharmaceuticals in a research note on Monday, April 21st. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $15.63.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in TERN. Candriam S.C.A. bought a new position in shares of Terns Pharmaceuticals during the 4th quarter worth approximately $11,933,000. Acorn Capital Advisors LLC bought a new position in shares of Terns Pharmaceuticals during the 4th quarter worth approximately $10,921,000. Soleus Capital Management L.P. boosted its stake in shares of Terns Pharmaceuticals by 30.8% during the 4th quarter. Soleus Capital Management L.P. now owns 8,142,500 shares of the company’s stock worth $45,109,000 after acquiring an additional 1,918,956 shares during the period. Schonfeld Strategic Advisors LLC boosted its stake in Terns Pharmaceuticals by 44.4% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 4,751,506 shares of the company’s stock valued at $26,323,000 after purchasing an additional 1,461,680 shares during the period. Finally, Nuveen LLC bought a new stake in Terns Pharmaceuticals in the 1st quarter valued at $3,880,000. 98.26% of the stock is currently owned by institutional investors.

Terns Pharmaceuticals Company Profile

Terns Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.